May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Effects of Sulfamethoxazole on Murine Ocular Toxoplasmosis in Interferon––Knockout Mice
Author Affiliations & Notes
  • K. Norose
    Infection/Host Defense, Grad Sch Med, Chiba Univ, Chiba–shi, Japan
  • F. Aosai
    Infection/Host Defense, Grad Sch Med, Chiba Univ, Chiba–shi, Japan
  • H.–S. Mun
    Infection/Host Defense, Grad Sch Med, Chiba Univ, Chiba–shi, Japan
  • A. Yano
    Infection/Host Defense, Grad Sch Med, Chiba Univ, Chiba–shi, Japan
  • Footnotes
    Commercial Relationships  K. Norose, None; F. Aosai, None; H. Mun, None; A. Yano, None.
  • Footnotes
    Support  17591822 for Scientific Research from the Japanese Science Promotion Society
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 291. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. Norose, F. Aosai, H.–S. Mun, A. Yano; Effects of Sulfamethoxazole on Murine Ocular Toxoplasmosis in Interferon––Knockout Mice . Invest. Ophthalmol. Vis. Sci. 2006;47(13):291.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the effects of sulfamethoxazole (SMX) on experimental ocular toxoplasmosis by quantitative competitive polymerase chain reaction (QC–PCR) assay.

Methods: : Wild type (WT) C57BL/6 and BALB/c mice and interferon–γ knockout (GKO) mice were infected orally with Toxoplasma gondii of the Fukaya strain. Mice were classified into groups. The first group (G1) remained untreated, the second group (G2) had a short SMX treatment period, and the third group (G3) received treatment continuously. WT and GKO mice were divided into G1 and G3, and G1, G2, and G3, respectively. T. gondii burdens were evaluated by QC–PCR assay. Effect on stage distribution was analyzed by reverse transcription–PCR.

Results: : SMX significantly decreased mortality among the infected WT C57BL/6 and GKO mice. In WT G1 mice, T. gondii DNA was detected in all organs and tissues, although in G3 mice it was detected only in the brain. In GKO C57BL/6 G1 mice, the protozoan proliferated much more actively than in WT mice. In the GKO C57BL/6 G2 mice, the number of T. gondii was less than that of G1 during the treatment, although the protozoan reappeared after cessation of treatment. In GKO C57BL/6 G3 mice, T. gondii DNA was detected in the brain, optic nerve and retina, but not in the iris, choroid, sclera, and blood. In GKO BALB/c mice, the patterns of the kinetics of protozoan abundance in various organs were similar or were milder than those in GKO C57BL/6 mice. In SMX–treated GKO mice, the percentage of bradyzoites increased and that of tachyzoites decreased in the organs and tissues.

Conclusions: : SMX decreased the parasitic load in both WT and GKO mice. SMX decreased the tachyzoite load but did not completely eliminate bradyzoites in GKO mice. The present mouse model was used successfully to assess treatment effects in a quantitative fashion.

Keywords: toxoplasmosis • drug toxicity/drug effects • AIDS/HIV 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×